Your browser doesn't support javascript.
loading
Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
Tan, David Cheng Thiam; Khong, Yuet Mei; Mount, Steven; Galella, Elizabeth; Mitra, Biplob; Charlton, Stuart; Kuhli, Maren; Ternik, Robert; Walsh, Jennifer; Rajapakshe, Asha; Thompson, Karen; Mehrotra, Shailly; Santangelo, Matthew; Liu, Jing; Dixit, Trupti; Schaufelberger, Daniel; Jamzad, Shahla; Klein, Sandra; Hoag, Stephen W; Wang, Jian; Fletcher, Elimika Pfuma; Khurana, Mona; Alexander, John; Radden, Erica; Sood, Ramesh; Selen, Arzu.
Affiliation
  • Tan DCT; AbbVie Inc., North Chicago, IL, United States. Electronic address: cheng.tan@abbvie.com.
  • Khong YM; AbbVie Inc., North Chicago, IL, United States.
  • Mount S; Astra Zeneca, Macclesfield, United Kingdom.
  • Galella E; Bristol-Myers Squibb, New Brunswick, NJ, United States.
  • Mitra B; Bristol-Myers Squibb, Summit, NJ, United States.
  • Charlton S; Bristol-Myers Squibb, Moreton, CH46 1QW, United Kingdom.
  • Kuhli M; Daiichi Sankyo Europe GmbH, 85276 Pfaffenhofen, Germany.
  • Ternik R; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.
  • Walsh J; Jenny Walsh Consulting Ltd, BioCity Nottingham, NG1 1GF, United Kingdom.
  • Rajapakshe A; Merck & Co Inc., West Point, PA, United States.
  • Thompson K; Merck & Co Inc., West Point, PA, United States.
  • Mehrotra S; Otsuka Pharmaceutical Development & Commercialization, Princeton, NJ, United States.
  • Santangelo M; Pfizer Inc., Groton, CT, United States.
  • Liu J; Pfizer Inc., Groton, CT, United States.
  • Dixit T; Pfizer Inc., Lake Forest, IL, United States.
  • Schaufelberger D; Schaufelberger Consulting LLC, NJ, United States.
  • Jamzad S; Sunovion Pharmaceuticals, Marlborough, MA, United States.
  • Klein S; University of Greifswald, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Greifswald, Germany.
  • Hoag SW; University of Maryland, School of Pharmacy, Baltimore, MD, United States.
  • Wang J; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Fletcher EP; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Khurana M; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Alexander J; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Radden E; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Sood R; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States.
  • Selen A; U.S. Food and Drug Administration (FDA), Silver Spring, MD, United States. Electronic address: arzu.Selen@fda.hhs.gov.
Eur J Pharm Biopharm ; 164: 54-65, 2021 Jul.
Article in En | MEDLINE | ID: mdl-33878432
ABSTRACT
A workshop on "Pediatric Formulation Development Challenges of Today and Strategies for Tomorrow" was organized jointly by the University of Maryland's Center of Excellence in Regulatory Science and Innovation (M-CERSI), the U.S. Food and Drug Administration (FDA) and the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Drug Product Pediatric Working Group (PWG). This multi-disciplinary, pediatric focused workshop was held over a two-day period (18-19 Jun 2019) and consisted of participants from industry, regulatory agencies, academia and other organizations from both US and Europe. The workshop consisted of sequential sessions on formulation, analytical, clinical, and regulatory and industry lessons learned and future landscape. Each session began with a series of short framing presentations, followed by facilitated breakout sessions and panel discussion. The formulation session was dedicated to three main topics pertaining to drug product acceptability, excipients in pediatrics and oral administration device considerations. The analytical session discussed key considerations for dosing vehicle selection and analytical strategies for testing of different dosage forms, specifically mini-tablets (multiparticulates). The clinical session highlighted the influence of pediatric pharmacokinetics prediction on formulation design, pediatric drug development strategies and clinical considerations to support pediatric formulation design. The regulatory and industry lessons learned and future landscape session explored the regional differences that exist in regulatory expectations, requirements for pediatric formulation development, and key patient-centric factors to consider when developing novel pediatric formulations. This session also discussed potential collaboration opportunities and tools for pediatric formulation development. This manuscript summarizes the key discussions and outcomes of all the sessions in the workshop with a broadened review and discussion of the topics that were covered.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tablets / Pharmaceutical Preparations / Drug Development Type of study: Prognostic_studies Limits: Child / Humans Language: En Journal: Eur J Pharm Biopharm Journal subject: FARMACIA / FARMACOLOGIA Year: 2021 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tablets / Pharmaceutical Preparations / Drug Development Type of study: Prognostic_studies Limits: Child / Humans Language: En Journal: Eur J Pharm Biopharm Journal subject: FARMACIA / FARMACOLOGIA Year: 2021 Document type: Article
...